Terminated PHASE3 INTERVENTIONAL 2-arm NCT01057901

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America

Sponsor: Sprout Pharmaceuticals, Inc

Conditions Sexual Dysfunctions, Psychological

Interventions Flibanserin Placebo

Updated 9 times since 2017 Last updated: Jun 16, 2014 Started: Jan 31, 2010 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated for administrative reasons.

Other terminated trials from Sprout Pharmaceuticals, Inc

More terminations from Sprout Pharmaceuticals, Inc

Other Sexual Dysfunctions, Psychological trials with similar outcome

Browse all Sexual Dysfunctions, Psychological trials

Listed as NCT01057901, this PHASE3 trial focuses on Sexual Dysfunctions, Psychological and remains terminated or withdrawn. Sponsored by Sprout Pharmaceuticals, Inc, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sprout Pharmaceuticals, Inc

Data source: Sprout Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anderson, United States , Ashland, United States , Austin, United States , Barrie, Canada , Beachwood, United States , Berkeley, United States , Birmingham, United States , Bismarck, United States , Boise, United States and 81 more locations